Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.60 |
---|---|
High | 26.60 |
Low | 26.60 |
Bid | 26.60 |
Offer | 29.20 |
Previous close | 26.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 1.95bn |
Free float | 1.95bn |
P/E (TTM) | 34.31 |
Market cap | 56.16bn USD |
EPS (TTM) | 0.8469 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:18 GMT.
More ▼
Press releases
- Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
- Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
- Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
- ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
- Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
- Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
- DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
- ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
- Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
More ▼